Search

Your search keyword '"Lancellotti P."' showing total 88 results
Start Over Author "Lancellotti P." Journal european heart journal
88 results on '"Lancellotti P."'

1. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)

Author

Lyon, A. R., Lopez-Fernandez, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., Cutter, D. J., de Azambuja, E., de Boer, R. A., Dent, S. F., Farmakis, D., Gevaert, S. A., Gorog, D. A., Herrmann, J., Lenihan, D., Moslehi, J., Moura, B., Salinger, S. S., Stephens, R., Suter, T. M., Szmit, S., Tamargo, J., Thavendiranathan, P., Tocchetti, C. G., van der Meer, P., van der Pal, H. J. H., Lancellotti, P., Thuny, F., Abdelhamid, M., Aboyans, V., Aleman, B., Alexandre, J., Barac, A., Borger, M. A., Casado-Arroyo, R., Cautela, J., Celutkiene, J., Cikes, M., Cohen-Solal, A., Dhiman, K., Ederhy, S., Edvardsen, T., Fauchier, L., Fradley, M., Grapsa, J., Halvorsen, S., Heuser, M., Humbert, M., Jaarsma, T., Kahan, T., Konradi, A., Koskinas, K. C., Kotecha, D., Ky, B., Landmesser, U., Lewis, B. S., Linhart, A., Lip, G. Y. H., Lochen, M. -L., Malaczynska-Rajpold, K., Metra, M., Mindham, R., Moonen, M., Neilan, T. G., Nielsen, J. C., Petronio, A. -S., Prescott, E., Rakisheva, A., Salem, J. -E., Savarese, G., Sitges, M., Ten Berg, J., Touyz, R. M., Tycinska, A., Wilhelm, M., Zamorano, J. L., Cardiovascular Centre (CVC), Restoring Organ Function by Means of Regenerative Medicine (REGENERATE), Group, ESC Scientific Document, Lyon, Alexander R, López-Fernández, Teresa, Couch, Liam S, Asteggiano, Riccardo, Aznar, Marianne C, Bergler-Klein, Jutta, Boriani, Giuseppe, Cardinale, Daniela, Cordoba, Raul, Cosyns, Bernard, Cutter, David J, de Azambuja, Evandro, de Boer, Rudolf A, Dent, Susan F, Farmakis, Dimitrio, Gevaert, Sofie A, Gorog, Diana A, Herrmann, Joerg, Lenihan, Daniel, Moslehi, Javid, Moura, Brenda, Salinger, Sonja S, Stephens, Richard, Suter, Thomas M, Szmit, Sebastian, Tamargo, Juan, Thavendiranathan, Paaladinesh, Tocchetti, Carlo G, van der Meer, Peter, van der Pal, Helena J H, Cardiology, Clinical sciences, and Cardio-vascular diseases

Subjects
Cardiac magnetic resonance, Cancer survivors, Vascular endothelial growth factor inhibitors (VEGFi), Myocarditi, Guideline, Anthracycline, Arrhythmias, Medical Oncology, T-CELL THERAPY, Coronary artery disease, Strain, RECURRENT VENOUS THROMBOEMBOLISM, Amyloid light-chain cardiac amyloidosis, Androgen deprivation therapy, Atrial fibrillation, Biomarkers, Cancer, Carcinoid syndrome, Cardiac tumour, Cardio-oncology, Cardiotoxicity, Chemotherapy, Echocardiography, Fluoropyrimidine, Guidelines, Haematopoietic stem cell transplantation, Heart failure, Hormone therapy, Hypertension, Immunotherapy, Ischaemic heart disease, Myocarditis, Pericardial disease, Proteasome inhibitors, Pulmonary hypertension, QTc prolongation, Radiotherapy, Risk stratification, Thrombosis, Trastuzumab, Valvular heart disease, Venous thromboembolism, Neoplasms, Proteasome inhibitor, Amyloid light-chain cardiac amyloidosi, IMMUNE CHECKPOINT INHIBITORS, Cardiotoxicity/diagnostic imaging, Heart, General Medicine, Hematology, MOLECULAR-WEIGHT HEPARIN, BRAIN NATRIURETIC PEPTIDE, oncology, Cancer survivor, Thrombosi, CORONARY-ARTERY-DISEASE, Cardiology and Cardiovascular Medicine, TYROSINE KINASE INHIBITOR, Arrhythmia, Neoplasms/diagnostic imaging, Antineoplastic Agents, Humans, Radiology, Nuclear Medicine and imaging, EARLY BREAST-CANCER, CARCINOID HEART-DISEASE, Antineoplastic Agents/therapeutic use, Biomarker, AORTIC-VALVE-REPLACEMENT, Radiation Oncology
Published
2022
Full Text
View/download PDF

2. Risk calculator to predict 30-day mortality in left-sided infective endocarditis. The EURO-ENDO score

Author

Lozano Torres, J, Sambola, A, Magne, J, Olmos, C, Ternacle, J, Calvo, F, Tribouilloy, Christophe, Reskovic Luksic, V, Separovic-Hanzevacki, J, Park, S, Cam Bekkers, S, Chan, K, Iung, B, Lancellotti, P, Habib, G, European Infective Endocarditis Registry (Euro-Endo), Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517 (MP3CV), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, CHU Amiens-Picardie, Chungbuk National University, Service de cardiologie [CHU Bichat], AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot, Sorbonne Paris Cité, Service de cardiologie [Liège], CHU de Liège-Domaine Universitaire du Sart Tilman, Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Département de Cardiologie [Hôpital de la Timone - APHM], and Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE)

Subjects
Cardiology and Cardiovascular Medicine, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

Background/Introduction Infective endocarditis (IE) is associated with high in-hospital mortality, despite improvements in therapeutic strategies. Nonetheless, there is no prospective risk model to estimate IE mortality. Purpose We sought to develop and validate a calculator to predict 30-day mortality risk regarding to perform surgery or medical treatment alone in left-sided IE. Methods This is a prospective, multicenter registry that included patients between January 2016 and March 2018 with a diagnosis of IE based on ESC 2015 diagnostic criteria. Patients with possible or definite left-sided IE were included in the analyses. Clinical, biological, microbiological and imaging data were collected. The primary end point was 30-day mortality in patients with left-sided IE. The risk calculator was based on multivariable Cox regression models. The accuracy of the logistic regression models was assessed by discrimination and calibration using C-statistic and Hosmer-Lemeshow test. Results Among 3116 patients included, 2171 patients presented left-sided IE and 257 patients (11.8%) died during the first 30 days of IE diagnosis. After multivariable Logistic regression analysis, eleven variables were associated with 30-days mortality and were included in the calculator: previous cardiac surgery, previous stroke/TIA, creatinine >2 mg/dL, S. aureus infection, embolic events on admission, heart failure or cardiogenic shock, vegetation size >14 mm, presence of abscess, severe regurgitation, double left-sided IE and no left valve surgery. There was an excellent correlation between the predicted 30-days mortality in both models with or without performing left valve surgery (area under the receiver operator curve: 0.798 and 0.758, respectively). Moreover, calibration by Hosmer-Lemeshow were 0.085 and 0.09, respectively). Conclusion(s) Our risk score in patients with left-sided IE provides an accurate individualized estimation of 30-day mortality according to perform or not perform left-valve surgery. It allows medical professionals to determine whether submitting patients to surgery or not, and thus improve their prognosis. Funding Acknowledgement Type of funding sources: None.

Published
2022
Full Text
View/download PDF

3. Characteristics, management, and outcomes of patients with left-sided infective endocarditis complicated by heart failure: a substudy of the ESC-EORP EURO-ENDO (European infective endocarditis) regist

Author

Bohbot, Y, primary, Habib, G, additional, Stohr, E, additional, Chirouze, C, additional, Hernandez-Meneses, M, additional, Melissopoulou, M, additional, Scheggi, V, additional, Branco, L, additional, Olmos, C, additional, Reye, G, additional, Pazdernik, M, additional, Iung, B, additional, Sow, R, additional, Lancellotti, P, additional, and Tribouilloy, C, additional

Published
2022
Full Text
View/download PDF

4. Clinical and haemodynamic effects of percutaneous edge-to-edge mitral valve repair in atrial versus ventricular functional mitral regurgitation

Author

Claeys, M J, primary, Debonnaire, P, additional, Bracke, V, additional, Bilotta, G, additional, Shkarpa, N, additional, Vanderheyden, M, additional, Coussement, P, additional, Vanderheyden, J, additional, Van De Heyning, C, additional, Cosyns, B, additional, Pouleur, A C, additional, Lancellotti, P, additional, Paelinck, B, additional, Ferdinande, B, additional, and Dubois, C, additional

Published
2021
Full Text
View/download PDF

5. ESC Core Curriculum for the General Cardiologist (2013)

Author

Gillebert, Thierry C., Brooks, Nicholas, Fontes-Carvalho, Ricardo, Fras, Zlatko, Gueret, Pascal, Lopez-Sendon, Jose, Salvador, Maria Jesus, van den Brink, Renee B. A., Smiseth, Otto A., Griebenow, Reinhard, Kearney, Peter, Vahanian, Alec, Bauersachs, J., Bax, J., Burri, H., Caforio, A.L.P., Calvo, F., Charron, P., Ertl, G., Flachskampf, F., Giannuzzi, P., Gibbs, S., Gonçalves, L., González-Juanatey, J.R., Hall, J., Herpin, D., Iaccarino, G., Iung, B., Kitsiou, A., Lancellotti, P., McDonough, T., Monsuez, J.J., Nuñez, I.J., Plein, S., Porta-Sánchez, A., Priori, S., Price, S., Regitz-Zagrosek, V., Reiner, Z., Ruilope, L.M., Schmid, J.P., Sirnes, P. A., Sousa-Ouva, M., Stępińska, J., Szymanski, C., Taggart, D., Tendera, M., Tokgözog[Combining Caron]lu, L., Trindade, P., Zeppenfeld, K., Joubert, L., and Carrera, C.

Published
2013
Full Text
View/download PDF

6. Age-related characteristics of infective endocarditis: prospective data from the Euro-Endo registry

Author

Pazdernik, M, primary, Selton-Suty, C, additional, Lancellotti, P, additional, Kong, W.K.F, additional, Srdanovic, I, additional, Yamada, H, additional, Riezebos, R.K, additional, De Martino, A, additional, Pierard, L, additional, Nunes, M, additional, Haertel Miglioranza, M, additional, Magne, J, additional, Mutlu, B, additional, Habib, G, additional, and Iung, B, additional

Published
2020
Full Text
View/download PDF

9. Cancer and Infective endocarditis: diagnosis and prognostic impact. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study

Author

Cosyns, B, primary, Roosens, B, additional, Lancellotti, P, additional, Marchetta, S, additional, Scheggi, V, additional, Vilacosta, I, additional, Pasquet, A, additional, Piper, C, additional, Reyes, G, additional, Mahfouz, E, additional, Kobalava, Z, additional, Piroth, L, additional, Kasprzak, J.D, additional, Iung, B, additional, and Habib, G, additional

Published
2020
Full Text
View/download PDF

15. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

Author

Rydén, L, Grant, Pj, Anker, Sd, Berne, C, Cosentino, F, Danchin, N, Deaton, C, Escaned, J, Hammes, Hp, Huikuri, H, Marre, M, Marx, N, Mellbin, L, Ostergren, J, Patrono, C, Seferovic, P, Uva, Ms, Taskinen, Mr, Tendera, M, Tuomilehto, J, Valensi, P, Zamorano, Jl, Achenbach, S, Baumgartner, H, Bax, Jj, Bueno, H, Dean, V, Erol, C, Fagard, R, Ferrari, R, Hasdai, D, Hoes, Aw, Kirchhof, P, Knuuti, J, Kolh, P, Lancellotti, P, Linhart, A, Nihoyannopoulos, P, Piepoli, Mf, Ponikowski, P, Sirnes, Pa, Tamargo, Jl, Torbicki, A, Wijns, W, Windecker, S, De Backer, G, Ezquerra, Ea, Avogaro, Angelo, Badimon, L, Baranova, E, Betteridge, J, Ceriello, A, Funck Brentano, C, Gulba, Dc, Kjekshus, Jk, Lev, E, Mueller, C, Neyses, L, Nilsson, Pm, Perk, J, Reiner, Z, Sattar, N, Schächinger, V, Scheen, A, Schirmer, H, Strömberg, A, Sudzhaeva, S, Viigimaa, M, Vlachopoulos, C, Xuereb, Rg, Authors/Task Force Members, ESC Committee for Practice Guidelines, and Document, Reviewers

Subjects
Male, Epidemiology, Smoking Prevention, Impaired glucose tolerance, Diabetes mellitus, Patient-Centered Care, Medicine, Child, Diagnostics, Smoking, Middle Aged, Cardiovascular disease, Prognosis, Patient management, Coronary Interventions, Cardiovascular Diseases, Pre diabetes, Child, Preschool, Female, Cardiology and Cardiovascular Medicine, Pharmacological treatment, Adult, medicine.medical_specialty, Adolescent, 610 Medicine & health, Guidelines, Prediabetic State, Young Adult, Internal medicine, Humans, Exercise, Aged, Glycated Hemoglobin, business.industry, Task force, Prevention, Settore MED/09 - MEDICINA INTERNA, Infant, medicine.disease, Diet, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Risk factors, business, Diabetic Angiopathies
Published
2013
Full Text
View/download PDF

16. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)

Author

Zamorano, JL, Lancellotti, P, Rodriguez Muñoz, D, Aboyans, V, Asteggiano, R, Galderisi, M, Habib, G, Lenihan, DJ, Lip, GY, Lyon, AR, Lopez Fernandez, T, Mohty, D, Piepoli, MF, Tamargo, J, Torbicki, A, Suter, TM, Achenbach, S, Agewall, S, Badimon, L, Barón-Esquivias, G, Baumgartner, H, Bax, JJ, Bueno, H, Carerj, S, Dean, V, Erol, Ç, Fitzsimons, D, Gaemperli, O, Kirchhof, P, Kolh, P, Nihoyannopoulos, P, Ponikowski, P, Roffi, M, Vaz Carneiro, A, Windecker, S, Authors/Task Force Members, ESC Committee for Practice Guidelines (CPG), University of Zurich, Zamorano, Jose Luis, Centre Hospitalier Universitaire de Liège (CHU-Liège), Neuroépidémiologie Tropicale (NET), CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Università degli studi di Napoli Federico II, Unité de Recherche sur les Maladies Infectieuses Tropicales Emergentes (URMITE), Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes (URMITE), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR48, INSB-INSB-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR48, INSB-INSB-Centre National de la Recherche Scientifique (CNRS), British Heart Foundation, Action Against Cancer, Zamorano, Jose Lui, Lancellotti, Patrizio, Rodriguez Muñoz, Daniel, Aboyans, Victor, Asteggiano, Riccardo, Galderisi, Maurizio, Habib, Gilbert, Lenihan, Daniel J., Lip, Gregory Y. H., Lyon, Alexander R., Lopez Fernandez, Teresa, Mohty, Dania, Piepoli, Massimo F., Tamargo, Juan, Torbicki, Adam, Suter, Thomas M., Achenbach, Stephan, Agewall, Stefan, Badimon, Lina, Barón Esquivias, Gonzalo, Baumgartner, Helmut, Bax, Jeroen J., Bueno, Héctor, Carerj, Scipione, Dean, Veronica, Erol, Çetin, Fitzsimons, Donna, Gaemperli, Oliver, Kirchhof, Paulu, Kolh, Philippe, Nihoyannopoulos, Petro, Ponikowski, Piotr, Roffi, Marco, Vaz Carneiro, António, Windecker, Stephan, Lenihan, Daniel J, Lip, Gregory Y. H, Lyon, Alexander R, Piepoli, Massimo F, University of Naples Federico II = Università degli studi di Napoli Federico II, Institut des sciences biologiques (INSB-CNRS)-Institut des sciences biologiques (INSB-CNRS)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR48, and Institut des sciences biologiques (INSB-CNRS)-Institut des sciences biologiques (INSB-CNRS)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Vascular Endothelial Growth Factor A, Angiotensin receptor, Cardiac & Cardiovascular Systems, cardio-oncology, medicine.medical_treatment, myocardial dysfunction, 030204 cardiovascular system & hematology, ANTHRACYCLINE-INDUCED CARDIOMYOPATHY, chemotherapy, Coronary artery disease, 0302 clinical medicine, RENAL-CELL CARCINOMA, Authors/Task Force Members, Cancer Survivors, Neoplasms, Natriuretic peptide, 610 Medicine & health, early detection, ComputingMilieux_MISCELLANEOUS, Societies, Medical, HER2-POSITIVE BREAST-CANCER, TRASTUZUMAB-INDUCED CARDIOTOXICITY, Chemotherapy regimen, 3. Good health, Europe, medicine.anatomical_structure, 030220 oncology & carcinogenesis, CHEMOTHERAPY-INDUCED CARDIOTOXICITY, Practice Guidelines as Topic, cardiovascular system, Cardiology, surveillance, 10209 Clinic for Cardiology, cancer therapy, CORONARY-ARTERY-DISEASE, ESC Committee for Practice Guidelines (CPG), ischaemia, Immunotherapy, Cardiology and Cardiovascular Medicine, Life Sciences & Biomedicine, arrhythmias, Arrhythmia, Artery, Cardiovascular toxicity, medicine.medical_specialty, Heart Diseases, medicine.drug_class, Advisory Committees, Cancer therapy, Early detection, Antineoplastic Agents, [SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/Surgery, 1102 Cardiovascular Medicine And Haematology, 2705 Cardiology and Cardiovascular Medicine, European Society of Cardiology, 03 medical and health sciences, LEFT-VENTRICULAR DYSFUNCTION, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Internal medicine, medicine, TYROSINE KINASE INHIBITORS, Humans, cardiovascular diseases, Intensive care medicine, ACUTE LYMPHOBLASTIC-LEUKEMIA, Cardiotoxicity, Science & Technology, CONGESTIVE-HEART-FAILURE, Radiotherapy, business.industry, Arrhythmias, Cardio-oncology, Chemotherapy, Ischaemia, Myocardial dysfunction, Surveillance, Cancer, 10181 Clinic for Nuclear Medicine, Congresses as Topic, medicine.disease, Radiation therapy, Cardiovascular System & Hematology, Cardiovascular System & Cardiology, Position paper, business, human activities, Document Reviewers
Abstract

2-D : two-dimensional 3-D : three-dimensional 5-FU : 5-fluorouracil ACE : angiotensin-converting enzyme ARB : angiotensin II receptor blocker ASE : American Society of Echocardiography BNP : B-type natriuretic peptide CABG : coronary artery bypass graft CAD : coronary artery

Published
2016
Full Text
View/download PDF

17. P2979Clinical significance of right ventricular longitudinal function parameters after aortic valve replacement

Author

Coisne, A., primary, Modine, T., additional, Outteryck, F., additional, Mouton, S., additional, Pilato, R., additional, Richardson, M., additional, Duva-Pentiah, A., additional, Madika, A.L., additional, Ledieu, G., additional, Boutie, B., additional, Jacquelinet, M., additional, Koussa, M., additional, Fayad, G., additional, Lancellotti, P., additional, and Montaigne, D., additional

Published
2017
Full Text
View/download PDF

18. Non-invasive cardiac imaging evaluation of patients with chronic systolic heart failure: a report from the European Association of Cardiovascular Imaging (EACVI)

Author

Gimelli, A., primary, Lancellotti, P., additional, Badano, L. P., additional, Lombardi, M., additional, Gerber, B., additional, Plein, S., additional, Neglia, D., additional, Edvardsen, T., additional, Kitsiou, A., additional, Scholte, A. J. H. A., additional, Schroder, S., additional, Cosyns, B., additional, Gargiulo, P., additional, Zamorano, J. L., additional, and Perrone-Filardi, P., additional

Published
2014
Full Text
View/download PDF

19. The appropriate and justified use of medical radiation in cardiovascular imaging: a position document of the ESC Associations of Cardiovascular Imaging, Percutaneous Cardiovascular Interventions and Electrophysiology

Author

Picano, E., primary, Vano, E., additional, Rehani, M. M., additional, Cuocolo, A., additional, Mont, L., additional, Bodi, V., additional, Bar, O., additional, Maccia, C., additional, Pierard, L., additional, Sicari, R., additional, Plein, S., additional, Mahrholdt, H., additional, Lancellotti, P., additional, Knuuti, J., additional, Heidbuchel, H., additional, Di Mario, C., additional, and Badano, L. P., additional

Published
2014
Full Text
View/download PDF

30. Myocardial viability.

Author

Piérard, L. A., Lancellotti, P., and Benoit, T.

Abstract

Myocardial dyssynergy does not necessarily indicate myocardial necrosis in patients with coronary artery disease. The differentiation between viable and non-viable tissue is of great clinical importance in order to make the most appropriate clinical decision in the individual patient. Several techniques are used to assess myocardial viability. Nuclear medicine gives reliable information on regional perfusion, metabolism and cell membrane integrity, while echocardiography provides real time visualization of myocardial thickening in basal conditions and continuously during pharmacological interventions. The presence or absence of contractile reserve in akinetic regions can be evaluated by pharmacological stress echocardiography.This article presents the semiology of myocardial viability as characterized by these different methods and reviews their relative value in different clinical settings. [ABSTRACT FROM PUBLISHER]

Published
1997

31. Multimodality imaging in cardiology: a statement on behalf of the Task Force on Multimodality Imaging of the European Association of Cardiovascular Imaging

Author

Gianluca Pontone, Gilbert Habib, Stephan Achenbach, Victoria Delgado, Bogdan A. Popescu, Danilo Neglia, Udo Sechtem, Patrizio Lancellotti, Frank A. Flachskampf, Ehud Schwammenthal, Bernard Cosyns, Mark Westwood, Thor Edvardsen, Denisa Muraru, Marc R. Dweck, Kevin Fox, Jeroen J. Bax, Leiden University Medical Center (LUMC), Oslo University Hospital [Oslo], Uppsala University, Microbes évolution phylogénie et infections (MEPHI), Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU), Assistance Publique-Hôpitaux de Marseille (AP-HM), Groupe Interdisciplinaire de Génoprotéomique Appliquée (GIGA-Research), Université de Liège, Universita degli Studi di Padova, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Fox, K, Achenbach, S, Bax, J, Cosyns, B, Delgado, V, Dweck, M, Edvardsen, T, Flachskampf, F, Habib, G, Lancellotti, P, Muraru, D, Neglia, D, Pontone, G, Schwammenthal, E, Sechtem, U, Westwood, M, Popescu, B, Universiteit Leiden, Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Assistance Publique - Hôpitaux de Marseille (APHM), Università degli Studi di Padova = University of Padua (Unipd), Clinical sciences, Cardio-vascular diseases, and Cardiology

Subjects
medicine.medical_specialty, Heart Diseases, Statement (logic), Association (object-oriented programming), Advisory Committees, Cardiology, MEDLINE, 030204 cardiovascular system & hematology, Multimodal Imaging, Multimodality, cardiovascular magnetic resonance, 03 medical and health sciences, 0302 clinical medicine, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Internal medicine, Medical imaging, Humans, Medicine, [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, Societies, Medical, ComputingMilieux_MISCELLANEOUS, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, business.industry, Task force, Heart, 030229 sport sciences, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, 3. Good health, Europe, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Cardiology and Cardiovascular Medicine, business
Abstract

Multimodality imaging in cardiology : a statement on behalf of the Task Force on Multimodality Imaging of the European Association of Cardiovascular Imaging

Published
2018
Full Text
View/download PDF

32. Non-invasive cardiac imaging evaluation of patients with chronic systolic heart failure: a report from the European Association of Cardiovascular Imaging (EACVI)

Author

Arthur J.H.A. Scholte, Danilo Neglia, Alessia Gimelli, Bernard Cosyns, Stephen Schröder, Anastasia Kitsiou, José Luis Zamorano, Paola Gargiulo, Sven Plein, Thor Edvardsen, Pasquale Perrone-Filardi, Patrizio Lancellotti, Luigi P. Badano, Massimo Lombardi, Bernhard Gerber, Gimelli, A, Lancellotti, P, Badano, L, Lombardi, M, Gerber, B, Plein, S, Neglia, D, Edvardsen, T, Kitsiou, A, Scholte, A, Schroder, S, Cosyns, B, Gargiulo, P, Zamorano, J, Perrone-Filardi, P, Gimelli, Alessia, Lancellotti, Patrizio, Badano, Luigi P., Lombardi, Massimo, Gerber, Bernhard, Plein, Sven, Neglia, Danilo, Edvardsen, Thor, Kitsiou, Anastasia, Scholte, Arthur J. H. A., Schröder, Stephen, Cosyns, Bernard, Gargiulo, Paola, Zamorano, Jose Lui, PERRONE FILARDI, Pasquale, and Clinical sciences

Subjects
medicine.medical_specialty, Consensus, Prognosi, medicine.medical_treatment, Left, Cardiac resynchronization therapy, Consensu, Multimodal Imaging, Sensitivity and Specificity, Follow-Up Studie, Coronary artery disease, Ventricular Dysfunction, Left, Cardiac Imaging Techniques, Chronic Disease, Follow-Up Studies, Heart Failure, Systolic, Humans, Prognosis, Cardiology and Cardiovascular Medicine, Medicine (all), Internal medicine, Ventricular Dysfunction, medicine, cardiovascular diseases, Myocardial infarction, Cardiac imaging, Heart Failure, Cardiac Imaging Technique, Ejection fraction, business.industry, MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE, medicine.disease, Implantable cardioverter-defibrillator, Brain natriuretic peptide, Heart failure, cardiovascular system, Cardiology, Radiology, business, Systolic, Human
Abstract

In patients with heart failure (HF) and reduced ejection fraction (EF), non-invasive cardiac imaging provides diagnostic, prognostic, and therapeutic information and assists decision-making. The aim of this consensus paper is to provide an overview of the clinical applications of non-invasive cardiac imaging in the management of HF patients with systolic dysfunction, mostly focusing on impact on clinical decision-making ( Figure 1 ). Figure 1 Use of cardiac imaging for the management of patients with chronic systolic heart failure. HF, heart failure; BNP, brain natriuretic peptide; CMR, cardiac magnetic resonance; EF, ejection fraction; CAD, coronary artery disease; CCTA, cardiac computed tomographic angiography; SPECT, single photon emission computed tomography; PET, positron emission tomography; ICD, implantable cardioverter defibrillator; CRT, cardiac resynchronization therapy; OMT, optimal medical therapy. *might precede stress imaging in patients with angina. In patients with suspected HF, an electrocardiogram, chest X-ray, and brain natriuretic peptide (BNP or NT-proBNP) assay should be performed before non-invasive cardiac imaging,1 but in particular clinical situations with high likelihood of the disease, i.e. symptoms of HF in patients with previous myocardial infarction, cardiac imaging might be directly performed without previous BNP assay. Left ventricular (LV) systolic dysfunction, conventionally identified when EF at rest is 60 mm or 32 mm/m2 with LV volume >97 mL/m2) and end-systolic diameter and …

Published
2014
Full Text
View/download PDF

33. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)

Author

Giuseppe, Mancia, Robert, Fagard, Krzysztof, Narkiewicz, Josep, Redon, Alberto, Zanchetti, Michael, Böhm, Thierry, Christiaens, Renata, Cifkova, Guy, De Backer, Anna, Dominiczak, Maurizio, Galderisi, Diederick E, Grobbee, Tiny, Jaarsma, Paulus, Kirchhof, Sverre E, Kjeldsen, Stéphane, Laurent, Athanasios J, Manolis, Peter M, Nilsson, Luis Miguel, Ruilope, Roland E, Schmieder, Per Anton, Sirnes, Peter, Sleight, Margus, Viigimaa, Bernard, Waeber, Faiez, Zannad, Michel, Burnier, Ettore, Ambrosioni, Mark, Caufield, Antonio, Coca, Michael Hecht, Olsen, Costas, Tsioufis, Philippe, van de Borne, Jose Luis, Zamorano, Stephan, Achenbach, Helmut, Baumgartner, Jeroen J, Bax, Héctor, Bueno, Veronica, Dean, Christi, Deaton, Cetin, Erol, Roberto, Ferrari, David, Hasdai, Arno W, Hoes, Juhani, Knuuti, Philippe, Kolh, Patrizio, Lancellotti, Ales, Linhart, Petros, Nihoyannopoulos, Massimo F, Piepoli, Piotr, Ponikowski, Juan Luis, Tamargo, Michal, Tendera, Adam, Torbicki, William, Wijns, Stephan, Windecker, Denis L, Clement, Thierry C, Gillebert, Enrico Agabiti, Rosei, Stefan D, Anker, Johann, Bauersachs, Jana Brguljan, Hitij, Mark, Caulfield, Marc, De Buyzere, Sabina, De Geest, Geneviève Anne, Derumeaux, Serap, Erdine, Csaba, Farsang, Christian, Funck-Brentano, Vjekoslav, Gerc, Giuseppe, Germano, Stephan, Gielen, Herman, Haller, Jens, Jordan, Thomas, Kahan, Michel, Komajda, Dragan, Lovic, Heiko, Mahrholdt, Jan, Ostergren, Gianfranco, Parati, Joep, Perk, Jorge, Polonia, Bogdan A, Popescu, Zeljko, Reiner, Lars, Rydén, Yuriy, Sirenko, Alice, Stanton, Harry, Struijker-Boudier, Charalambos, Vlachopoulos, Massimo, Volpe, David A, Wood, Mancia, G, Fagard, R, Narkiewicz, K, Redon, J, Zanchetti, A, Böhm, M, Christiaens, T, Cifkova, R, De Backer, G, Dominiczak, A, Galderisi, M, Grobbee, D, Jaarsma, T, Kirchhof, P, Kjeldsen, S, Laurent, S, Manolis, A, Nilsson, P, Ruilope, L, Schmieder, R, Sirnes, P, Sleight, P, Viigimaa, M, Waeber, B, Zannad, F, Burnier, M, Ambrosioni, E, Caufield, M, Coca, A, Olsen, M, Tsioufis, C, Van De Borne, P, Zamorano, J, Achenbach, S, Baumgartner, H, Bax, J, Bueno, H, Dean, V, Deaton, C, Erol, C, Ferrari, R, Hasdai, D, Hoes, A, Knuuti, J, Kolh, P, Lancellotti, P, Linhart, A, Nihoyannopoulos, P, Piepoli, M, Ponikowski, P, Tamargo, J, Tendera, M, Torbicki, A, Wijns, W, Windecker, S, Clement, D, Gillebert, T, Rosei, E, Anker, S, Bauersachs, J, Hitij, J, Caulfield, M, De Buyzere, M, De Geest, S, Derumeaux, G, Erdine, S, Farsang, C, Funck Brentano, C, Gerc, V, Germano, G, Gielen, S, Haller, H, Jordan, J, Kahan, T, Komajda, M, Lovic, D, Mahrholdt, H, Ostergren, J, Parati, G, Perk, J, Polonia, J, Popescu, B, Reiner, Ž, Rydén, L, Sirenko, Y, Stanton, A, Struijker Boudier, H, Vlachopoulos, C, Volpe, M, Wood, D, Mancia, Giuseppe, Fagard, Robert, Narkiewicz, Krzysztof, Redon, Josep, Zanchetti, Alberto, Böhm, Michael, Christiaens, Thierry, Cifkova, Renata, De Backer, Guy, Dominiczak, Anna, Galderisi, Maurizio, Grobbee, Diederick E., Jaarsma, Tiny, Kirchhof, Paulu, Kjeldsen, Sverre E., Laurent, Stéphane, Manolis, Athanasios J., Nilsson, Peter M., Ruilope, Luis Miguel, Schmieder, Roland E., Sirnes, Per Anton, Sleight, Peter, Viigimaa, Margu, Waeber, Bernard, Zannad, Faiez, Burnier, Michel, Ambrosioni, Ettore, Caufield, Mark, Coca, Antonio, Olsen, Michael Hecht, Tsioufis, Costa, Van De Borne, Philippe, Zamorano, Jose Lui, Achenbach, Stephan, Baumgartner, Helmut, Bax, Jeroen J., Bueno, Héctor, Dean, Veronica, Deaton, Christi, Erol, Cetin, Ferrari, Roberto, Hasdai, David, Hoes, Arno W., Knuuti, Juhani, Kolh, Philippe, Lancellotti, Patrizio, Linhart, Ale, Nihoyannopoulos, Petro, Piepoli, Massimo F., Ponikowski, Piotr, Tamargo, Juan Lui, Tendera, Michal, Torbicki, Adam, Wijns, William, Windecker, Stephan, Clement, Denis L., Gillebert, Thierry C., Rosei, Enrico Agabiti, Anker, Stefan D., Bauersachs, Johann, Hitij, Jana Brguljan, Caulfield, Mark, De Buyzere, Marc, De Geest, Sabina, Derumeaux, Geneviève Anne, Erdine, Serap, Farsang, Csaba, Funck Brentano, Christian, Gerc, Vjekoslav, Germano, Giuseppe, Gielen, Stephan, Haller, Herman, Jordan, Jen, Kahan, Thoma, Komajda, Michel, Lovic, Dragan, Mahrholdt, Heiko, Ostergren, Jan, Parati, Gianfranco, Perk, Joep, Polonia, Jorge, Popescu, Bogdan A., Reiner, Željko, Rydén, Lar, Sirenko, Yuriy, Stanton, Alice, Struijker Boudier, Harry, Vlachopoulos, Charalambo, Volpe, Massimo, and Wood, David A.

Subjects
Male, Systolic hypertension, Medical Informatic, Blood Pressure, Guideline, Retinal Disease, chemistry.chemical_compound, Electrocardiography, Pregnancy, Risk Factors, Antihypertensive treatment, Cardiovascular Disease, Diabetes Complication, Drug Interactions, Metabolic Syndrome, Brain Diseases, Sleep Apnea, Obstructive, Follow-up, Metabolic Syndrome X, Brain Disease, Organ damage, Blood Pressure Monitoring, Ambulatory, Middle Aged, Device therapy, Antihypertensive Agent, Heart Disease, Drug Interaction, Cardiovascular Diseases, Echocardiography, Cerebrovascular Disorder, Hypertension, Cardiology, Drug Therapy, Combination, Female, Cardiology and Cardiovascular Medicine, Human, medicine.drug, Adult, medicine.medical_specialty, Ambulatory blood pressure, Heart Diseases, Hormone Replacement Therapy, 610 Medicine & health, Risk Assessment, Perioperative Care, Diabetes Complications, Young Adult, Retinal Diseases, Internal medicine, Weight Loss, medicine, Humans, Blood pressure measurement, Renal Insufficiency, Chronic, Exercise, Physical Examination, Perindopril/indapamide, Antihypertensive Agents, Aged, Patient Care Team, business.industry, Platelet Aggregation Inhibitor, Risk Factor, Cardiovascular complication, Hypertension, Pregnancy-Induced, Aliskiren, Cardiovascular risk, Lifestyle, medicine.disease, Weight Lo, Diet, Candesartan, Cerebrovascular Disorders, Sexual Dysfunction, Physiological, Blood pressure, chemistry, Heart failure, Hyperglycemia, Smoking Cessation, Telmisartan, business, Delivery of Health Care, Risk Reduction Behavior, Medical Informatics, Platelet Aggregation Inhibitors, Contraceptives, Oral
Abstract

ABCD : Appropriate Blood pressure Control in Diabetes ABI : ankle–brachial index ABPM : ambulatory blood pressure monitoring ACCESS : Acute Candesartan Cilexetil Therapy in Stroke Survival ACCOMPLISH : Avoiding Cardiovascular Events in Combination Therapy in Patients Living with Systolic Hypertension ACCORD : Action to Control Cardiovascular Risk in Diabetes ACE : angiotensin-converting enzyme ACTIVE I : Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events ADVANCE : Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation AHEAD : Action for HEAlth in Diabetes ALLHAT : Antihypertensive and Lipid-Lowering Treatment to Prevent Heart ATtack ALTITUDE : ALiskiren Trial In Type 2 Diabetes Using Cardio-renal Endpoints ANTIPAF : ANgioTensin II Antagonist In Paroxysmal Atrial Fibrillation APOLLO : A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People ARB : angiotensin receptor blocker ARIC : Atherosclerosis Risk In Communities ARR : aldosterone renin ratio ASCOT : Anglo-Scandinavian Cardiac Outcomes Trial ASCOT-LLA : Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm ASTRAL : Angioplasty and STenting for Renal Artery Lesions A-V : atrioventricular BB : beta-blocker BMI : body mass index BP : blood pressure BSA : body surface area CA : calcium antagonist CABG : coronary artery bypass graft CAPPP : CAPtopril Prevention Project CAPRAF : CAndesartan in the Prevention of Relapsing Atrial Fibrillation CHD : coronary heart disease CHHIPS : Controlling Hypertension and Hypertension Immediately Post-Stroke CKD : chronic kidney disease CKD-EPI : Chronic Kidney Disease—EPIdemiology collaboration CONVINCE : Controlled ONset Verapamil INvestigation of CV Endpoints CT : computed tomography CV : cardiovascular CVD : cardiovascular disease D : diuretic DASH : Dietary Approaches to Stop Hypertension DBP : diastolic blood pressure DCCT : Diabetes Control and Complications Study DIRECT : DIabetic REtinopathy Candesartan Trials DM : diabetes mellitus DPP-4 : dipeptidyl peptidase 4 EAS : European Atherosclerosis Society EASD : European Association for the Study of Diabetes ECG : electrocardiogram EF : ejection fraction eGFR : estimated glomerular filtration rate ELSA : European Lacidipine Study on Atherosclerosis ESC : European Society of Cardiology ESH : European Society of Hypertension ESRD : end-stage renal disease EXPLOR : Amlodipine–Valsartan Combination Decreases Central Systolic Blood Pressure more Effectively than the Amlodipine–Atenolol Combination FDA : U.S. Food and Drug Administration FEVER : Felodipine EVent Reduction study GISSI-AF : Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation HbA1c : glycated haemoglobin HBPM : home blood pressure monitoring HOPE : Heart Outcomes Prevention Evaluation HOT : Hypertension Optimal Treatment HRT : hormone replacement therapy HT : hypertension HYVET : HYpertension in the Very Elderly Trial IMT : intima-media thickness I-PRESERVE : Irbesartan in Heart Failure with Preserved Systolic Function INTERHEART : Effect of Potentially Modifiable Risk Factors associated with Myocardial Infarction in 52 Countries INVEST : INternational VErapamil SR/T Trandolapril ISH : Isolated systolic hypertension JNC : Joint National Committee JUPITER : Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin LAVi : left atrial volume index LIFE : Losartan Intervention For Endpoint Reduction in Hypertensives LV : left ventricle/left ventricular LVH : left ventricular hypertrophy LVM : left ventricular mass MDRD : Modification of Diet in Renal Disease MRFIT : Multiple Risk Factor Intervention Trial MRI : magnetic resonance imaging NORDIL : The Nordic Diltiazem Intervention study OC : oral contraceptive OD : organ damage ONTARGET : ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial PAD : peripheral artery disease PATHS : Prevention And Treatment of Hypertension Study PCI : percutaneous coronary intervention PPAR : peroxisome proliferator-activated receptor PREVEND : Prevention of REnal and Vascular ENdstage Disease PROFESS : Prevention Regimen for Effectively Avoiding Secondary Strokes PROGRESS : Perindopril Protection Against Recurrent Stroke Study PWV : pulse wave velocity QALY : Quality adjusted life years RAA : renin-angiotensin-aldosterone RAS : renin-angiotensin system RCT : randomized controlled trials RF : risk factor ROADMAP : Randomized Olmesartan And Diabetes MicroAlbuminuria Prevention SBP : systolic blood pressure SCAST : Angiotensin-Receptor Blocker Candesartan for Treatment of Acute STroke SCOPE : Study on COgnition and Prognosis in the Elderly SCORE : Systematic COronary Risk Evaluation SHEP : Systolic Hypertension in the Elderly Program STOP : Swedish Trials in Old Patients with Hypertension STOP-2 : The second Swedish Trial in Old Patients with Hypertension SYSTCHINA : SYSTolic Hypertension in the Elderly: Chinese trial SYSTEUR : SYSTolic Hypertension in Europe TIA : transient ischaemic attack TOHP : Trials Of Hypertension Prevention TRANSCEND : Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease UKPDS : United Kingdom Prospective Diabetes Study VADT : Veterans' Affairs Diabetes Trial VALUE : Valsartan Antihypertensive Long-term Use Evaluation WHO : World Health Organization ### 1.1 Principles The 2013 guidelines on hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology …

Published
2013
Full Text
View/download PDF

35. Predictors of embolism and death in left-sided infective endocarditis: the European Society of Cardiology EURObservational Research Programme European Infective Endocarditis registry.

Author

Sambola A, Lozano-Torres J, Boersma E, Olmos C, Ternacle J, Calvo F, Tribouilloy C, Reskovic-Luksic V, Separovic-Hanzevacki J, Park SW, Bekkers S, Chan KL, Almaghraby A, Iung B, Lancellotti P, and Habib G

Subjects
Humans, Female, Prospective Studies, Registries, Risk Factors, Retrospective Studies, Endocarditis, Bacterial complications, Endocarditis surgery, Embolism complications, Cardiology
Abstract

Background and Aims: Even though vegetation size in infective endocarditis (IE) has been associated with embolic events (EEs) and mortality risk, it is unclear whether vegetation size associated with these potential outcomes is different in left-sided IE (LSIE). This study aimed to seek assessing the vegetation cut-off size as predictor of EE or 30-day mortality for LSIE and to determine risk predictors of these outcomes., Methods: The European Society of Cardiology EURObservational Research Programme European Infective Endocarditis is a prospective, multicentre registry including patients with definite or possible IE throughout 2016-18. Cox multivariable logistic regression analysis was performed to assess variables associated with EE or 30-day mortality., Results: There were 2171 patients with LSIE (women 31.5%). Among these affected patients, 459 (21.1%) had a new EE or died in 30 days. The cut-off value of vegetation size for predicting EEs or 30-day mortality was >10 mm [hazard ratio (HR) 1.38, 95% confidence interval (CI) 1.13-1.69, P = .0015]. Other adjusted predictors of risk of EE or death were as follows: EE on admission (HR 1.89, 95% CI 1.54-2.33, P < .0001), history of heart failure (HR 1.53, 95% CI 1.21-1.93, P = .0004), creatinine >2 mg/dL (HR 1.59, 95% CI 1.25-2.03, P = .0002), Staphylococcus aureus (HR 1.36, 95% CI 1.08-1.70, P = .008), congestive heart failure (HR 1.40, 95% CI 1.12-1.75, P = .003), presence of haemorrhagic stroke (HR 4.57, 95% CI 3.08-6.79, P < .0001), alcohol abuse (HR 1.45, 95% CI 1.04-2.03, P = .03), presence of cardiogenic shock (HR 2.07, 95% CI 1.29-3.34, P = .003), and not performing left surgery (HR 1.30 95% CI 1.05-1.61, P = .016) (C-statistic = .68)., Conclusions: Prognosis after LSIE is determined by multiple factors, including vegetation size., (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)

Published
2023
Full Text
View/download PDF

37. Outcomes of culture-negative vs. culture-positive infective endocarditis: the ESC-EORP EURO-ENDO registry.

Author

Kong WKF, Salsano A, Giacobbe DR, Popescu BA, Laroche C, Duval X, Schueler R, Moreo A, Colonna P, Piper C, Calvo-Iglesias F, Badano LP, Srdanovic I, Boutoille D, Huttin O, Stöhr E, Timóteo AT, Vaskelyte JJ, Sadeghpour A, Tornos P, Abid L, Poh KK, Habib G, and Lancellotti P

Subjects
Humans, Proportional Hazards Models, Registries, Retrospective Studies, Cardiac Surgical Procedures adverse effects, Endocarditis diagnosis, Endocarditis epidemiology, Endocarditis, Bacterial diagnosis, Endocarditis, Bacterial epidemiology, Endocarditis, Bacterial therapy
Abstract

Aim: Fatality of infective endocarditis (IE) is high worldwide, and its diagnosis remains a challenge. The objective of the present study was to compare the clinical characteristics and outcomes of patients with culture-positive (CPIE) vs. culture-negative IE (CNIE)., Methods and Results: This was an ancillary analysis of the ESC-EORP EURO-ENDO registry. Overall, 3113 patients who were diagnosed with IE during the study period were included in the present study. Of these, 2590 (83.2%) had CPIE, whereas 523 (16.8%) had CNIE. As many as 1488 (48.1%) patients underwent cardiac surgery during the index hospitalization, 1259 (48.8%) with CPIE and 229 (44.5%) with CNIE. The CNIE was a predictor of 1-year mortality [hazard ratio (HR) 1.28, 95% confidence interval (CI) 1.04-1.56], whereas surgery was significantly associated with survival (HR 0.49, 95% CI 0.41-0.58). The 1-year mortality was significantly higher in CNIE than CPIE patients in the medical subgroup, but it was not significantly different in CNIE vs. CPIE patients who underwent surgery., Conclusion: The present analysis of the EURO-ENDO registry confirms a higher long-term mortality in patients with CNIE compared with patients with CPIE. This difference was present in patients receiving medical therapy alone and not in those who underwent surgery, with surgery being associated with reduced mortality. Additional efforts are required both to improve the aetiological diagnosis of IE and identify CNIE cases early before progressive disease potentially contraindicates surgery., (© The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)

Published
2022
Full Text
View/download PDF

38. Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease.

Author

Ten Berg J, Sibbing D, Rocca B, Van Belle E, Chevalier B, Collet JP, Dudek D, Gilard M, Gorog DA, Grapsa J, Grove EL, Lancellotti P, Petronio AS, Rubboli A, Torracca L, Vilahur G, Witkowski A, and Mehilli J

Subjects
Aged, Aortic Valve surgery, Consensus, Fibrinolytic Agents therapeutic use, Humans, Treatment Outcome, Aortic Valve Stenosis drug therapy, Aortic Valve Stenosis surgery, Heart Valve Diseases, Heart Valve Prosthesis Implantation, Thrombosis drug therapy, Thrombosis etiology, Thrombosis prevention & control, Transcatheter Aortic Valve Replacement adverse effects
Abstract

Transcatheter aortic valve implantation (TAVI) is effective in older patients with symptomatic severe aortic stenosis, while the indication has recently broadened to younger patients at lower risk. Although thromboembolic and bleeding complications after TAVI have decreased over time, such adverse events are still common. The recommendations of the latest 2017 ESC/EACTS Guidelines for the management of valvular heart disease on antithrombotic therapy in patients undergoing TAVI are mostly based on expert opinion. Based on recent studies and randomized controlled trials, this viewpoint document provides updated therapeutic insights in antithrombotic treatment during and after TAVI., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.)

Published
2021
Full Text
View/download PDF

44. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).

Author

Pieske B, Tschöpe C, de Boer RA, Fraser AG, Anker SD, Donal E, Edelmann F, Fu M, Guazzi M, Lam CSP, Lancellotti P, Melenovsky V, Morris DA, Nagel E, Pieske-Kraigher E, Ponikowski P, Solomon SD, Vasan RS, Rutten FH, Voors AA, Ruschitzka F, Paulus WJ, Seferovic P, and Filippatos G

Subjects
Aged, Consensus, Echocardiography, Female, Heart Failure, Diastolic etiology, Heart Failure, Diastolic physiopathology, Heart Ventricles diagnostic imaging, Heart Ventricles physiopathology, Humans, Male, Middle Aged, Natriuretic Peptides blood, Practice Guidelines as Topic, Algorithms, Cardiology organization & administration, Clinical Decision-Making, Heart Failure, Diastolic diagnosis
Abstract

Making a firm diagnosis of chronic heart failure with preserved ejection fraction (HFpEF) remains a challenge. We recommend a new stepwise diagnostic process, the 'HFA-PEFF diagnostic algorithm'. Step 1 (P=Pre-test assessment) is typically performed in the ambulatory setting and includes assessment for HF symptoms and signs, typical clinical demographics (obesity, hypertension, diabetes mellitus, elderly, atrial fibrillation), and diagnostic laboratory tests, electrocardiogram, and echocardiography. In the absence of overt non-cardiac causes of breathlessness, HFpEF can be suspected if there is a normal left ventricular ejection fraction, no significant heart valve disease or cardiac ischaemia, and at least one typical risk factor. Elevated natriuretic peptides support, but normal levels do not exclude a diagnosis of HFpEF. The second step (E: Echocardiography and Natriuretic Peptide Score) requires comprehensive echocardiography and is typically performed by a cardiologist. Measures include mitral annular early diastolic velocity (e'), left ventricular (LV) filling pressure estimated using E/e', left atrial volume index, LV mass index, LV relative wall thickness, tricuspid regurgitation velocity, LV global longitudinal systolic strain, and serum natriuretic peptide levels. Major (2 points) and Minor (1 point) criteria were defined from these measures. A score ≥5 points implies definite HFpEF; ≤1 point makes HFpEF unlikely. An intermediate score (2-4 points) implies diagnostic uncertainty, in which case Step 3 (F1: Functional testing) is recommended with echocardiographic or invasive haemodynamic exercise stress tests. Step 4 (F2: Final aetiology) is recommended to establish a possible specific cause of HFpEF or alternative explanations. Further research is needed for a better classification of HFpEF., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.)

Published
2019
Full Text
View/download PDF

45. Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study.

Author

Habib G, Erba PA, Iung B, Donal E, Cosyns B, Laroche C, Popescu BA, Prendergast B, Tornos P, Sadeghpour A, Oliver L, Vaskelyte JJ, Sow R, Axler O, Maggioni AP, and Lancellotti P

Subjects
Adult, Africa, Northern epidemiology, Aged, Aged, 80 and over, Asia epidemiology, Community-Acquired Infections diagnostic imaging, Community-Acquired Infections epidemiology, Echocardiography statistics & numerical data, Endocarditis, Bacterial epidemiology, Endocarditis, Bacterial microbiology, Enterococcus, Europe epidemiology, Female, Fluorodeoxyglucose F18, Heart Valve Prosthesis adverse effects, Hospital Mortality, Humans, Male, Middle Aged, Prospective Studies, Prosthesis-Related Infections diagnostic imaging, Prosthesis-Related Infections epidemiology, Radiopharmaceuticals, Registries, South America epidemiology, Staphylococcal Infections complications, Streptococcal Infections complications, Treatment Outcome, Embolism microbiology, Endocarditis, Bacterial diagnostic imaging, Endocarditis, Bacterial therapy, Positron Emission Tomography Computed Tomography statistics & numerical data
Abstract

Aims: The EURO-ENDO registry aimed to study the management and outcomes of patients with infective endocarditis (IE)., Methods and Results: Prospective cohort of 3116 adult patients (2470 from Europe, 646 from non-ESC countries), admitted to 156 hospitals in 40 countries between January 2016 and March 2018 with a diagnosis of IE based on ESC 2015 diagnostic criteria. Clinical, biological, microbiological, and imaging [echocardiography, computed tomography (CT) scan, 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT)] data were collected. Infective endocarditis was native (NVE) in 1764 (56.6%) patients, prosthetic (PVIE) in 939 (30.1%), and device-related (CDRIE) in 308 (9.9%). Infective endocarditis was community-acquired in 2046 (65.66%) patients. Microorganisms involved were staphylococci in 1085 (44.1%) patients, oral streptococci in 304 (12.3%), enterococci in 390 (15.8%), and Streptococcus gallolyticus in 162 (6.6%). 18F-fluorodeoxyglucose positron emission tomography/computed tomography was performed in 518 (16.6%) patients and presented with cardiac uptake (major criterion) in 222 (42.9%) patients, with a better sensitivity in PVIE (66.8%) than in NVE (28.0%) and CDRIE (16.3%). Embolic events occurred in 20.6% of patients, and were significantly associated with tricuspid or pulmonary IE, presence of a vegetation and Staphylococcus aureus IE. According to ESC guidelines, cardiac surgery was indicated in 2160 (69.3%) patients, but finally performed in only 1596 (73.9%) of them. In-hospital death occurred in 532 (17.1%) patients and was more frequent in PVIE. Independent predictors of mortality were Charlson index, creatinine > 2 mg/dL, congestive heart failure, vegetation length > 10 mm, cerebral complications, abscess, and failure to undertake surgery when indicated., Conclusion: Infective endocarditis is still a life-threatening disease with frequent lethal outcome despite profound changes in its clinical, microbiological, imaging, and therapeutic profiles., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.)

Published
2019
Full Text
View/download PDF

46. Cardio-Oncology Services: rationale, organization, and implementation.

Author

Lancellotti P, Suter TM, López-Fernández T, Galderisi M, Lyon AR, Van der Meer P, Cohen Solal A, Zamorano JL, Jerusalem G, Moonen M, Aboyans V, Bax JJ, and Asteggiano R

Subjects
Cardiology education, Humans, Medical Oncology education, Patient Care Team, Cardiology organization & administration, Cardiovascular Diseases diagnosis, Cardiovascular Diseases prevention & control, Cardiovascular Diseases therapy, Medical Oncology organization & administration, Models, Organizational, Neoplasms diagnosis, Neoplasms prevention & control, Neoplasms therapy
Abstract

Aims: Anticancer therapies have extended the lives of millions of patients with malignancies, but for some this benefit is tempered by adverse cardiovascular (CV) effects. Cardiotoxicity may occur early or late after treatment initiation or termination. The extent of this cardiotoxicity is variable, depending on the type of drug used, combination with other drugs, mediastinal radiotherapy, the presence of CV risk factors, and comorbidities. A recent position paper from the European Society of Cardiology addressed the management of CV monitoring and management of patients treated for cancer., Methods and Results: The current document is focused on the basis of the Cardio-Oncology (C-O) Services, presenting their rationale, organization, and implementation. C-O Services address the spectrum of prevention, detection, monitoring, and treatment of cancer patients at risk of cardiotoxicity and/or with concomitant CV diseases. These services require a multidisciplinary approach, with the aims of promoting CV health and facilitating the most effective cancer therapy., Conclusion: The expected growing volume of patients with cancer at risk of developing/worsening CV disease, the advent of new technological opportunities to refine diagnosis, and the necessity of early recognition of cancer therapy-related toxicity mandate an integrative multidisciplinary approach and care in a specialized environment. This document from the ESC Cardio-Oncology council proposes the grounds for creating C-O Services in Europe based on expert opinion., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2018. For permissions, please email: journals.permissions@oup.com.)

Published
2019
Full Text
View/download PDF

47. Multimodality imaging in cardiology: a statement on behalf of the Task Force on Multimodality Imaging of the European Association of Cardiovascular Imaging.

Author

Fox K, Achenbach S, Bax J, Cosyns B, Delgado V, Dweck MR, Edvardsen T, Flachskampf F, Habib G, Lancellotti P, Muraru D, Neglia D, Pontone G, Schwammenthal E, Sechtem U, Westwood M, and Popescu BA

Subjects
Advisory Committees, Cardiology methods, Europe, Heart Diseases diagnostic imaging, Humans, Multimodal Imaging methods, Societies, Medical, Cardiology standards, Heart diagnostic imaging, Multimodal Imaging standards
Published
2019
Full Text
View/download PDF

50. European Association of Preventive Cardiology (EAPC) and European Association of Cardiovascular Imaging (EACVI) joint position statement: recommendations for the indication and interpretation of cardiovascular imaging in the evaluation of the athlete's heart.

Author

Pelliccia A, Caselli S, Sharma S, Basso C, Bax JJ, Corrado D, D'Andrea A, D'Ascenzi F, Di Paolo FM, Edvardsen T, Gati S, Galderisi M, Heidbuchel H, Nchimi A, Nieman K, Papadakis M, Pisicchio C, Schmied C, Popescu BA, Habib G, Grobbee D, and Lancellotti P

Subjects
Cardiology, Echocardiography, Europe, Humans, Magnetic Resonance Imaging, Myocardial Perfusion Imaging, Risk Assessment, Societies, Medical, Tomography, X-Ray Computed, Athletes, Cardiomegaly, Exercise-Induced, Heart diagnostic imaging, Heart Diseases diagnostic imaging
Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results